Vyome Q1 net loss $963K, cash $8.8M, inks JAK inhibitor licensing deal with Impetis

Vyome Holdings, Inc

2026-Q1 EPS reported -$0.15 vs consensus -$0.18 ▲ beat (+18.3%)

Net loss of approx. $963K ($0.15 per share) for Q1 ended March 31, 2026.
Cash and equivalents $8.8M, up from $5.0M at Dec 31, 2025; no debt or toxic financing.
In-licensed two selective JAK inhibitor assets from Impetis Biosciences (TATA Enterprise) for global ~$57B market.
Filed Orphan Drug Designation application for VT-1953 with FDA; submitted proposals for pivotal development guidance.
Raised $5.29M via sale of 1,089,545 shares at $5.00 (59.2% premium to prior close); ~15% dilution.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.97

Vyome Holdings, Inc reported first quarter ended March 31, 2026 results: net income Net loss attributable to common shareholders for the quarter ended March 31, 2026, was approximately $963,000, or approx, EPS approximately $0.15 per basic and diluted share.

Period: first quarter ended March 31, 2026
Net income: Net loss attributable to common shareholders for the quarter ended March 31, 2026, was approximately $963,000, or approx
EPS: approximately $0.15 per basic and diluted share
Result: reported results

Exact text from the filing

Vyome Holdings, Inc. issued a press release announcing its financial results for its first fiscal quarter ended March 31, 2026.

View on SEC.gov

Browse all earnings releases →

Vyome Holdings, Inc filing history →

Source: SEC EDGAR

accession 0001213900-26-062458

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.